Regenerativ medicin...(host,host..partnerskap)

Christian mejlar in överraskande info.Det brittiska företaget Jellagen med verksamhet beskriven enligt :

Collagen is the most abundant protein in the human body and is critical for healthy cell function and healing as well as providing key structural component for bones, muscles, skin, and tendons. 

In the medical field, collagen is used in a range of procedures including tissue reconstruction and wound management. 

Scientists also use collagen in routine cell culture applications as it provides a natural scaffold for cells to grow under conditions like those found within the human body. 

Collagen is also used in a variety of food and cosmetic products. For most applications, collagen is processed from mammalian sources including pigs, cows and rats which carry the risk of disease and virus transfer when used in humans. 

Jellagen sources its collagen from a single species of jellyfish which not only avoids these risks but also delivers superior healing benefits in human applications. 

Jellagen has established development collaborations with top research organisations in the US and Europe to investigate and confirm these findings and recent data supporting the advantages of marine collagen have been published in peer-reviewed scientific research articles.

 

Jellagen was founded in 2015 and has already established a range of products for the cell culture reagent market. 

After five years of intensive research including collaborations with top institutions in the US and Europe, the Company has completed a pre-clinical data set in proven animal models used to support the use of marine collagen in humans, including tissue reconstruction, diabetic wound healing and other medical applications. 

The Company will use these to explore development and licensing arrangements with potential pharma and medical device companies with established market positions in these applications.

 

Today Jellagen is led by a world-class team with experience across pharma, biotech, medical devices and investment banking. They bring strong scientific, clinical, and market development along with excellent commercial and business expertise. View the full Jellagen board, management team and Scientific Advisory Board here.

Where Art Meets Science!

Showcase the beauty of your research and WIN, with our image competition!

We have teamed up with our Live Cell Imaging Partner Phase Holographic Imaging to deliver our very first Image Competition. Simply purchase any Jellagen product from one of our distributors, use in your research, create some beautiful imagery and submit before the deadline to be in with a chance to win!

Our judges will be looking for not only the beauty of your image but also the quality of data behind it. Good Luck!

The Judges

Dr Andy Weymann MD MBA, Chief Medical Officer, Jellagen

Immediately prior to joining Jellagen, Andy was Chief Medical Officer (CMO) for Smith+Nephew, where he provided global executive leadership and oversight of Clinical, Scientific and Medical Affairs with accountability for business development, patient and product safety. He was also a Board Member of S+N Switzerland and a Board Member of Actracsys, a company acquired by S+N. Prior to his corporate career, Andy was a physician in Switzerland practising in trauma, orthopaedic surgery and sports medicine, having obtained his Masters in Human Medicine at the University of Zurich, Switzerland. Following his time as a Medical Doctor, Andy completed his MBA degree at the Simon Business School, University of Rochester NY as well expanding his experience with the board program at the Harvard Business School in Boston MA.

Kersti Alm PhD, Chief Scientific Officer, Phase Holographic Imaging PHI AB

Kersti has cooperated with PHI since 2005, while still employed at Lund University, and has been a vital part of the PHI team since 2009. All insights gained throughout her years as a Postdoc at Roswell Park Cancer Institute and Assistant and Associate Professor at Lund University have been applied to develop a genuinely novel cell analysis system. The focus has been to develop holography-based methods that will neither cause cell stress nor harm while providing accurate kinetic data. Digital holographic imaging has existed as a brainchild since the ’70s. Now, it is a reality since computers have become powerful enough to handle the algorithms required. Kersti has been part of developing digital holography for cell microscopy. And as such, she is a vital player as PHI advances cutting-edge research by supplying researchers worldwide with an advanced digital holographic microscope for cell-based science.

Dr Jennifer Paxton, Senior Lecturer in Anatomy, The University of Edinburgh

Och såhär presenterar Jellagen sin nya partner :

PHI`s nätverk av samarbetspartners inom den snabbt växande regenerativa medicinen innefattar nu inte bara jänkarna.Minns VD-orden från rapporten :

- Med ovanstående i åtanke inledde vi nyligen ett samarbete med RegenMed Development Organization (ReMDO) för att etablera vår icke-invasiva bildteknik som ett standardverktyg för kvalitetssäkring inom storskalig tillverkning av konstgjorda organ."

Standardverktyg? Innebär vad? frågar Bill.
Stort,jättestort svarar Bull.

 

                                         Mvh the99